Loading...
XSHE300171
Market cap1.31bUSD
Jan 15, Last price  
12.57CNY
1D
3.60%
1Q
5.50%
Jan 2017
-14.98%
IPO
15.72%
Name

Tofflon Science and Technology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300171 chart
P/E
15.93
P/S
1.70
EPS
0.79
Div Yield, %
2.61%
Shrs. gr., 5y
3.47%
Rev. gr., 5y
24.10%
Revenues
5.64b
+3.15%
167,224,594216,248,562308,065,550480,617,136648,865,071821,857,9441,021,120,6211,258,693,7061,555,556,0691,327,836,6021,724,879,1801,916,821,8922,264,004,3282,707,688,1624,192,421,1075,469,426,3625,641,696,442
Net income
600m
-29.10%
45,975,21653,385,42675,875,578142,844,836217,402,530233,328,902266,362,878335,411,145386,685,252234,511,455123,097,84270,457,732145,814,757463,493,693827,775,241846,569,056600,237,388
CFO
-312m
L
32,324,23156,174,914119,108,275118,385,926113,473,861347,375,486338,950,15155,060,521140,664,561107,413,33820,916,734222,035,747446,307,7381,115,814,5391,368,930,358247,153,989-312,382,622
Dividend
Jul 12, 20240.23919 CNY/sh
Earnings
May 22, 2025

Profile

Tofflon Science and Technology Group Co., Ltd. operates as a pharmaceutical equipment supplier for the pharma and biotech industries worldwide. It offers injectables, such as auto solution preparation systems, aseptic filling lines for ampoule, vials, syringes and powders, freeze dryer and auto loading systems, barrier systems, and plastic packaging machines. The company also provides active pharmaceutical ingredients; and visual inspection, leak detection, and combination systems, as well as focuses on providing bio-process equipment and integrated systems, including medium preparation, cell/microbial cultivation, harvesting, DF/UF, purification, buffer preparation, and finished filling systems. In addition, it offers lyophilization injectable lab services. The company was formerly known as Shanghai Tofflon Science and Technology Co., Ltd. The company was founded in 1993 and is headquartered in Shanghai, China.
URL
http://www.tofflon.com/
IPO date
Feb 01, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,641,696
3.15%
5,469,426
30.46%
Cost of revenue
4,552,053
4,103,356
Unusual Expense (Income)
NOPBT
1,089,644
1,366,070
NOPBT Margin
19.31%
24.98%
Operating Taxes
62,319
99,374
Tax Rate
5.72%
7.27%
NOPAT
1,027,325
1,266,696
Net income
600,237
-29.10%
846,569
2.27%
Dividends
(249,322)
(245,051)
Dividend yield
1.82%
1.62%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,343
4,273
Long-term debt
2,873
2,625
Deferred revenue
99,314
77,036
Other long-term liabilities
29,432
23,595
Net debt
(2,581,519)
(4,994,827)
Cash flow
Cash from operating activities
(312,383)
247,154
CAPEX
(694,590)
Cash from investing activities
(1,893,093)
Cash from financing activities
(223,561)
2,094,420
FCF
(470,359)
17,320
Balance
Cash
2,833,642
4,992,771
Long term investments
(245,908)
8,953
Excess cash
2,305,650
4,728,253
Stockholders' equity
4,036,765
4,256,807
Invested Capital
5,937,330
3,363,327
ROIC
22.09%
58.21%
ROCE
13.20%
17.85%
EV
Common stock shares outstanding
759,794
636,518
Price
17.99
-24.19%
23.73
-53.05%
Market cap
13,668,697
-9.51%
15,104,574
-53.06%
EV
11,317,411
10,311,205
EBITDA
1,180,117
1,431,647
EV/EBITDA
9.59
7.20
Interest
3,500
316
Interest/NOPBT
0.32%
0.02%